Ligand Targretin Gel Shows 28% Response Rate in Early-Stage CTCL
This article was originally published in Pharmaceutical Approvals Monthly
Labeling for Ligand’s recently approved Targretin (bexarotene) gel reports a 28% overall response rate (confidence interval of 14.6% to 40.3%) among patients with Stage IA and IB cutaneous T-cell lymphoma (CTCL).
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class